clinical trial · NCT06073873
A Post-Marketing Surveillance Study to Assess Safety of Ozanimod in Patients With Moderate to Severe Active UC in Korea
Bristol-Myers Squibb·—·recruiting·n = 3,000
Ulcerative ColitisOzanimod
brief summary
The purpose of this observational study is to assess the real-world safety of ozanimod in Korean participants with moderate to severe active ulcerative colitis.
started
Apr 19, 2024
primary completion
Apr 1, 2028
completion
Apr 1, 2028
last updated
Aug 22, 2024
official title
Post-Marketing Surveillance (PMS) Study on Zeposia® (Ozanimod) Use Among Moderate to Severe Active Ulcerative Colitis Patients in Korea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol